Schrodinger, Inc. (SDGR) Stock Price & Analysis

Schrodinger, Inc. (SDGR) rose 0.83% to USD 14.52 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.

SDGR last closed at USD 14.4; the session ranged USD 14.09–15.04 on volume of 927,971 shares. Market capitalization is $1.08B, with a 52-week range of USD 10.95–27.63 (NMS). Source: Nexqual, June 10, 2026 at 02:23 UTC.

Key Statistics (as of June 10, 2026 at 02:23 UTC)

Technical Analysis (SDGR)

Nexqual's technical model rates SDGR "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:23 UTC.

Analyst Ratings (SDGR)

Wall Street analysts rate SDGR "None" based on 8 analysts, with a mean price target of USD 20.88 (range USD 13–30), per Nexqual as of June 10, 2026 at 02:23 UTC.

Earnings (SDGR)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:23 UTC.

Financials & Fundamentals (SDGR)

Source: Nexqual, June 10, 2026 at 02:23 UTC.

Financial Health Score (SDGR)

Nexqual rates Schrodinger, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:23 UTC.

Ownership (SDGR)

Source: Nexqual, June 10, 2026 at 02:23 UTC.

Leadership (SDGR)

Schrodinger, Inc. is led by Ramy Farid (age 60), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:23 UTC.

Major Backers & Investors (SDGR)

Notable institutional backers of Schrodinger, Inc. include Gates Foundation Trust, Rubric Capital Management LP, Sumitomo Mitsui Trust Group, Inc., according to Nexqual as of June 10, 2026 at 02:23 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:23 UTC.

From Schrodinger, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Platform Over the past several decades since our founding in 1990, and with the concerted effort of hundreds of our scientists and software engineers, we have developed a computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy.
• Our Proprietary Drug Discovery Programs In 2018, we began to develop a pipeline of proprietary drug discovery programs with the goal of using our platform to produce a portfolio of novel, high value therapeutics.
• The following is a summary of our proprietary drug discovery programs: Our Approach to Target Selection Our selection of targets is based on an extensive analysis of human targets and drug discovery programs.
• In June 2025, the FDA granted fast track designation for SGR-1505 for the treatment of adult patients with Waldenström macroglobulinemia, or WM, that have failed at least two lines of therapy, including a Bruton's tyrosine kinase, or BTK, inhibitor.

Partnerships

• For example, in November 2024, we entered into an expanded, three-year, software agreement with Novartis, which is more fully described in "— Collaboration Agreements ." The three-year agreement substantially increases Novartis' access to our computational predictive modeling technology and enterprise informatics platform to industry-leading scale.
• We are eligible to receive up to $2.272 billion in total milestones across the initial programs, of which no milestone revenue has been recognized as revenue as of December 31, 2025, as well as a tiered percentage royalty on net sales of each product commercialized by Novartis ranging from mid-single-digits to low double-digits, subject to certain specified reductions.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.